Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Glutamine × 1 year × Clear all
NCT05852990 2026-04-09

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Instituto Nacional de Cancerologia de Mexico

Phase 3 Recruiting
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07287592 2025-12-17

Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.

Ain Shams University

Phase 3 Not yet recruiting
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡